New clinical trial for "Lactobacillus LJ88" approaching stomach discomfort.

The "Lactobacillus LJ88 (Lactobacillus johnsonii No.1088) heat-killed cells," which have been supplied since April 2016, have shown effectiveness in improving gastroesophageal reflux-related symptoms through oral intake in basic research using animals and pilot clinical trials. Additionally, animal experiments have confirmed that oral intake significantly increases the levels of bifidobacteria in feces, demonstrating its effects on both the stomach and intestines, making it a new type of lactic acid bacteria. We have recently conducted a randomized, placebo-controlled, double-blind parallel-group comparative clinical trial using "Lactobacillus LJ88 heat-killed cells" and confirmed its effectiveness in improving temporary and mild heartburn symptoms in healthy individuals. A summary of the paper's content has been published, so please check it out.

Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration